COMMUNIQUÉS West-GlobeNewswire
-
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
08/12/2025 -
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
08/12/2025 -
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
08/12/2025 -
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
08/12/2025 -
Imviva Biotech Presents Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias at the 67th American Society of Hematology Annual Meeting
08/12/2025 -
International study offers new path to reduce spinal taps in young infants with fevers
08/12/2025 -
Nelipak® Acquires Merrill’s Packaging
08/12/2025 -
Surgery Partners and Baylor Scott & White Health Form Joint Venture to Expand Access to Quality Care
08/12/2025 -
Ipsen - Novembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08/12/2025 -
Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
08/12/2025 -
Zelluna ASA - Mandatory notification of trade
08/12/2025 -
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS
08/12/2025 -
Hemp Hop Expands with New Cannabis Dispensary in Houston
08/12/2025 -
Moleculin Announces New Annamycin Collaboration in Brain Tumors
08/12/2025 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
08/12/2025 -
NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
08/12/2025 -
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
08/12/2025 -
Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
08/12/2025 -
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
08/12/2025
Pages